Търсене на изпитвания

Намерени 4,436 изпитвания Стр. 68 от 222

Набира участници Фаза 3

A Study of Brenipatide in Participants With Alcohol Use Disorder

Alcohol Use Disorder

The purpose of this study is to see if brenipatide when compared to a placebo works and is safe for participants with Alcohol Use Disorder (AUD) and hazardous alcohol use. Participation in this study will last approximately 56 weeks.

Начало: 16.10.2025 Край: 01.04.2028 Възраст: 18–75 г.

Belgium, China, Germany +5 Eli Lilly and Company NCT07219953

Набира участници

PACT Involvement in Cardiology Patients

Machine Learning Cardiovascular Outcome Pediatric Palliative Care Pediatric Cardiology

The goal of this trial is to determine the effectiveness of a machine-learning (ML) model predicting a serious cardiac event within the next three months, when compared pre- versus post-deployment, in pediatric cardiac inpatients. The main questions it aims to answer are whether deployment of the ML model: 1. Increases PACT consultation within the next three months among admissions without PACT involvement in the previous 100 days 2. Increases PACT consultation or visit within the next three months among those who experience a serious cardiac event during this period 3. Decreases time to PACT consultation or visit among those seen by PACT during this period 4. Decreases the incidence of death in the intensive care unit (ICU) 5. Increases documentation of goals of care High-risk cardiology patients will be identified by an ML model each morning. If the patient has been seen by the PACT team within the past year, the update will go to the PACT team members. If the patient hasn't been seen by the PACT team, the email will be sent to the cardiology physician in charge of the patient. This physician will decide whether a PACT consultation is necessary based on their clinical judgment. If so, a referral will be made using the usual process. Outcomes of the identified patients will be compared pre- and post-deployment.

Начало: 16.10.2025 Край: 16.10.2027 Възраст: до 18 г.

Canada The Hospital for Sick Children NCT06886529

Набира участници Фаза 1

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ZT003 Injection Following Single and Multiple Subcutaneous Administration in Healthy Volunteers/Overweight or Obese Volunteers

Healthy

This is a Phase 1, randomized, double-blind, placebo-controlled, single-center study designed to evaluate the safety, tolerability, and pharmacokinetics of ZT003 following subcutaneous administration in healthy adult participants. The study includes both single ascending dose (SAD) and multiple ascending dose (MAD) parts.

Начало: 16.10.2025 Край: 10.10.2026 Възраст: 18–65 г. Лечение

Australia Beijing QL Biopharmaceutical Co.,Ltd NCT07184502

Набира участници Фаза 2

A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes

Obesity Overweight Diabetes Mellitus, Type 2

The purpose of this study is to investigate weight reduction with macupatide and eloralintide, alone or in combination, in adult participants with obesity or overweight and with type 2 diabetes. Participation in the study will last about 48 weeks.

Начало: 16.10.2025 Край: 01.05.2027 Възраст: 18–75 г. Лечение

Argentina, Australia, Puerto Rico +1 Eli Lilly and Company NCT07215559

Набира участници

Safety and Effectiveness Evaluation of the High-intensity Focused Ultrasound Device for Lifting Lax Submental and Neck Tissue

Skin Laxity (Submental and Neck) Facial Skin Laxity Submental Tissue Laxity

This is a prospective, multicenter, randomized, evaluator-blinded, parallel-controlled, non-inferiority clinical study designed to evaluate the safety and effectiveness of the ULTRAFORMER MPT PLUS, a high-intensity focused ultrasound (HIFU) device, for lifting and tightening lax submental (beneath the chin) and neck tissue in adult subjects. Approximately 273 subjects will be enrolled at multiple investigational sites across the United States. Participants will receive either the ULTRAFORMER MPT PLUS treatment or the predicate comparator device, and will be followed for safety and efficacy assessments including clinical photography, investigator evaluation, and patient-reported outcomes. The study aims to demonstrate that ULTRAFORMER MPT PLUS is non-inferior to the approved reference device in improving skin laxity and wrinkle appearance of the lower face and neck.

Начало: 16.10.2025 Край: 26.11.2026 Възраст: 30–65 г.

United States CLASSYS Inc. NCT07229430

Набира участници

The Effect of Stress Ball on Nausea, Anxiety, and Fatigue in Patients With Stomach Cancer

Stomach Cancer Chemotherapy-induced Nausea and Vomiting Fatigue

In this study, we will observe the effects of the Stress Ball.

Начало: 15.10.2025 Край: 24.05.2026 Възраст: 18–80 г.

Turkey (Türkiye) Yuzuncu Yil University NCT07540169

Набира участници Фаза 2

A Phase 2 Trial to Investigate Efficacy and Safety of Vipoglanstat in Women With Endometriosis

Endometriosis

The main objective of the trial is to evaluate the efficacy of vipoglanstat on endometriosis-related non-menstrual pelvic pain (NMPP).

Начало: 15.10.2025 Край: 01.06.2027 Възраст: 18–44 г.

Bulgaria, Czechia, Hungary +4 Gesynta Pharma AB NCT07260669

Набира участници Фаза 1

A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease

Alzheimer's Disease

The purpose of this study is to: * Evaluate the safety and tolerability of intrathecal (IT) ALN-5288 in patients with Alzheimer's Disease (AD) * Evaluate the pharmacodynamic (PD) and pharmacokinetic (PK) effects of ALN-5288 after dose administration

Начало: 15.10.2025 Край: 06.03.2030 Възраст: 40–80 г.

Canada, Netherlands, Spain +1 Alnylam Pharmaceuticals NCT07214727

Набира участници

CAPIVASERTIB REGULATORY POSTMARKETING SURVEILLANCE IN KOREA

Breast Cancer

To fulfil the post-approval commitment of MFDS to conduct post-marketing surveillance, this study is designed to assess the known safety profile, identify previously unsuspected adverse reactions and to evaluate the effectiveness of Capivasertib under conditions of routine daily medical practice in Korea.

Начало: 15.10.2025 Край: 30.12.2029 Възраст: от 19 г.

South Korea AstraZeneca NCT06927648

Набира участници Фаза 3

A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use Disorder

Alcohol Use Disorder

The purpose of this study is to see if brenipatide when compared to a placebo works and is safe for participants with moderate-to-severe Alcohol Use Disorder (AUD). Participation in this study will last approximately 56 weeks.

Начало: 15.10.2025 Край: 01.04.2028 Възраст: 18–75 г.

Belgium, China, Germany +5 Eli Lilly and Company NCT07219966

Набира участници Фаза 3

A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

Metabolic Dysfunction-Associated Steatotic Liver Disease

The main purpose of the SYNERGY-OUTCOMES study is to find out whether retatrutide and tirzepatide can prevent major adverse liver outcomes (MALO) in people with high-risk metabolic dysfunction-associated steatotic liver disease (MASLD). The study will enroll adults who have MASLD based on non-invasive tests (NITs), which indicate they are more likely to develop MALO. Participants will be randomly assigned within a Master Protocol to receive either retatrutide (N1T-MC-RT01), tirzepatide (N1T-MC-TZ01) or placebo. The trial plans to enroll about 4,500 adults and will run for approximately 224 weeks. Participants may have up to approximately 25 to 30 clinic visits throughout the study to monitor their health, complete study procedures, and assess liver function and disease progression. Once the study is complete, eligible participants may participate in an optional 2-year extension study, in which all participants will receive either retatrutide or tirzepatide, even if they received placebo in the main study.

Начало: 15.10.2025 Край: 01.08.2032 Възраст: от 18 г. Лечение

Argentina, Australia, Belgium +29 Eli Lilly and Company NCT07165028

Набира участници

Wearable Technology and Machine Learning for Early Detection and Risk Assessment of Unacceptable Toxicities in a Paediatric Oncology Cohort

Cancer Infection Digital Health Wearable Devices

Data collection study to establish a predictive model of infection observed during childhood cancer therapy using data captured by wearable technology.

Начало: 15.10.2025 Край: 01.12.2027 Възраст: 5–18 г.

Australia Murdoch Childrens Research Institute NCT07030998

Набира участници

Effects of Spinal vs General Anesthesia on Systemic Inflammation in PCNL

Anesthesia Techniques Percutaneous Nephrolithotomy Systemic Inflammation

This observational study aims to compare the effects of spinal and general anesthesia on perioperative systemic inflammatory response in patients undergoing percutaneous nephrolithotomy (PCNL). Systemic inflammatory indices derived from routine complete blood count parameters, including Systemic Immune-Inflammation Index (SII), Systemic Inflammation Response Index (SIRI), Aggregate Index of Systemic Inflammation (AISI), Neutrophil-to-Lymphocyte Ratio (NLR), and Red Cell Distribution Width (RDW), will be evaluated. Preoperative and postoperative laboratory values will be analyzed to determine whether the type of anesthesia influences systemic inflammatory markers and related clinical outcomes.

Начало: 15.10.2025 Край: 30.04.2026 Възраст: от 18 г.

Turkey (Türkiye) Elazıg Fethi Sekin Sehir Hastanesi NCT07326670

Набира участници

PRIORITY-CONNECT 2 Trial

Colorectal Cancer Colorectal Neoplasms

Objectives: The primary aim of this project is to establish the effectiveness of an individualised stepped, multidisciplinary intervention, including education and peer support group, delivered via a virtual multimodal (p)rehabilitation hub, in reducing postoperative complications within 30-days following colorectal cancer surgery, compared to usual care alone. The secondary aims will be to obtain data on the likely difference in key outcomes including: (i) Quality of life (EORTC QLQ-C30 and QLQ-CR29) (ii) Number of days at home within 30, 90 and 365 days after surgery (DAH-30, 90, 365) (iii) Quality of recovery (QoR-15) (iv) Cost-effectiveness (v) Implementation metrics (RE-AIM) Our hypothesis is that the PRIORITY-CONNECT 2 intervention will be more effective in reducing postoperative complications and more cost-effective than usual care. Study design: Pragmatic Randomised Type I Hybrid Effectiveness-Implementation Trial. Planned sample size: To achieve the primary aim, 564 participants will provide 90% power to detect a 15% difference in 30-day postoperative complication rates between the intervention and control groups. The sample size calculation accounts for up to 10% loss to follow-up, 5% non-compliance and a two-side alpha of 0.05. Selection criteria: A sample of 564 participants undergoing colorectal cancer surgery including open, laparoscopic or robotic-assisted surgery (mostly, anterior resection, sigmoid colectomy, hemicolectomy, total proctocolectomy, subtotal colectomy, total colectomy) at sites throughout Australia will be included. These are common colorectal cancer surgeries performed at the participating centres. All the surgeons involved in this study have clinical appointments in their respective hospitals. Inclusion: Adults aged ≥18 years undergoing elective major surgery for colon or rectal cancer with curative intent; and consulting a colorectal surgeon at least 1 week prior to scheduled surgery. Exclusion: Patients undergoing Pelvic Exenteration (PE), Cytoreductive Surgery (CRS) with or without HIPEC, or concurrent surgery for metastatic disease; or cognitive impairment such that they are unable to provide informed consent. Study Procedure: Participant's treating team will screen and provide an information sheet about the trial to consecutive patients. Interested patients will be contacted by a study researcher to discuss the trial further, answer any questions, confirm eligibility against the inclusion and exclusion criteria, and consent patients. Consenting patients will undergo baseline assessment and be randomised to a virtual multimodal hub (Intervention group) or usual care alone (Control group). The intervention will include the delivery of usual care and evidence-based exercise, nutritional, psychological and nursing interventions, and / or group-delivered peer support. All interventions will be conducted before and after surgery. Duration of the Study: Approximately 60 months. Funding: Medical Research Future Fund (MRFF) 2023 Early and Mid-Career Researchers (Application ID: 2031563). Sponsor: The University of Sydney.

Начало: 15.10.2025 Край: 30.07.2028 Възраст: от 18 г. Поддържаща грижа

Australia Surgical Outcomes Research Centre (SOuRCe) NCT06976710

Набира участници Фаза 1/2

An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)

Progressive Metastatic Castrate Resistant Prostate Cancer

This is a two-part, Phase I/II, open-label, global, multicenter study assessing the safety and efficacy of the combination of tulmimetostat (DZR123) and JSB462 (luxdegalutamide) versus standard of care in participants with progressive metastatic castrate resistant prostate cancer (mCRPC).

Начало: 15.10.2025 Край: 01.12.2030 Възраст: от 18 г. Лечение

Australia, Canada, China +9 Novartis Pharmaceuticals NCT07206056

Набира участници

Patient Outcomes Following Kinematic and Functional Alignment in Robotic-Assisted Total Knee Arthroplasty With Randomized Insert Types

Knee Osteoarthritis Degenerative Joint Disease of the Knee

This study aims to evaluate patient outcomes following robotic-assisted total knee arthroplasty using the VELYS system. Patients undergoing surgery will receive either kinematic alignment or functional alignment as determined by the operating surgeon as part of routine clinical care. Within each surgical technique group, patients will be randomly assigned to receive different implant insert types (medial stabilised or cruciate retaining) using a REDCap-based randomisation process. Patient-reported outcome measures will be collected before surgery and at follow-up time points after surgery to assess clinical outcomes.

Начало: 14.10.2025 Край: 14.10.2027 Възраст: от 18 г.

Singapore Singapore General Hospital NCT07533188

Набира участници

Pain Disengagement Training (Open Pilot)

Chronic Musculoskeletal Pain

The investigators aim to conduct an open pilot trial to determine the initial feasibility of a self-directed writing-based intervention in individuals with chronic musculoskeletal pain and elevated pain catastrophizing. The investigators will assess the feasibility of recruitment, acceptability of the treatment, credibility and participant satisfaction, treatment adherence, and feasibility of assessments following pre-specified benchmarks.

Начало: 14.10.2025 Край: 30.06.2026 Възраст: от 18 г.

United States Massachusetts General Hospital NCT06870162

Набира участници Фаза 1/2

A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer

Small-cell Lung Cancer Neuroendocrine Carcinomas Solid Tumor Show to Express DLL3

This is Phase 1/2, multicenter, clinical study to evaluate the safety, efficacy, PK, and immunogenicity of IDE849 in subjects with DLL3-expressing tumors including SCLC.

Начало: 14.10.2025 Край: 01.05.2029 Възраст: от 18 г. Лечение

Australia, Brazil, Canada +4 IDEAYA Biosciences NCT07174583

Набира участници Фаза 3

A Study to Evaluate the Efficacy and Safey of PTP-001 (MOTYS™) in Knee Osteoarthritis Patients

Knee Osteoarthritis

This is a multicenter, prospective, randomized, double-blind, placebo-controlled, parallel-arm, Phase 3 study of intra-articular administration of PTP-001 (MOTYS) for the treatment of knee osteoarthritis. The purpose of the trial is to evaluate the efficacy, safety, and tolerability of a single intra-articular injection of PTP-001 compared to placebo over a 52-week period in participants with radiographic and symptomatic knee OA.

Начало: 14.10.2025 Край: 01.10.2027 Възраст: 40–80 г. Лечение

Australia Doron Therapeutics Inc. NCT07219771

Набира участници Фаза 3

B7981028 - A LONG-TERM, DOUBLE-BLIND EXTENSION STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF RITLECITINIB IN PARTICIPANTS WITH SEVERE ALOPECIA AREATA WHO PREVIOUSLY COMPLETED STUDIES B7981027 OR B7981031

Alopecia areata

Trial status: Authorised • Response based on achieving absolute Severity of Alopecia Tool (SALT) score ≤10 at all visits. • Response based on achieving absolute SALT score ≤20 at all visits • Change from baseline (CFB) in SALT score at all visits. • Response based on achieving at least 2 grade improvement or a score of 3 in eyebrow assessment (EBA) score at all visits in participants with an abnormal EBA at baseline., • Response based on achieving at least 2 grade improvement or a score of 3 in eyelash assessment (ELA) score at all visits in participants with an abnormal ELA at baseline. • Patient Global Impression of Change (PGI-C) response defined as score of “moderately improved or greatly improved” at all time points., • CFB in Patient Reported Outcomes Measurement Information System (PROMIS) Parent Proxy Depressive Symptoms T-score at all visits. • CFB in PROMIS Parent Proxy Anxiety Symptoms T-score at all visits., • CFB in Behavior Rating Inventory of Executive Function®2 (BRIEF®2) T-scores for the three index scores (Behavior Regulation Index [BRI], Emotional Regulation Index [ERI], Cognitive Regulation Index [CRI]) at all visits., • CFB in modified Children's Dermatology Life Quality Index (CDLQI) total score at all visits. • CFB# in Wechsler Intelligence Scale for Children® Fifth Edition (WISC-V) at end of study (Month 36). • Incidence of treatment-emergent adverse events (AEs). • Incidence of serious AEs (SAEs) and AEs leading to permanent discontinuation from the study.

Начало: 14.10.2025

Czech Republic, France, Italy +2 Pfizer Inc. 2024-515439-31-00

1 … 66 67 68 69 70 … 222